Amylyx Pharmaceuticals, Inc. filings document a clinical-stage biotechnology issuer developing investigational therapies in endocrine conditions and neurodegenerative diseases. Its 8-K reports furnish quarterly and annual financial results, corporate presentations and material-event disclosures tied to programs such as avexitide for post-bariatric hypoglycemia, AMX0318 and AMX0035.
Proxy and material-event filings describe governance, executive compensation, shareholder voting matters, common-stock registration on the Nasdaq Global Select Market, capital-structure matters, material agreements and program decisions. These records also capture collaboration economics, development-candidate selections, expanded pipeline disclosures and formal updates to clinical programs.
An insider of the company with ticker AMLX has filed a notice of intent to sell 136,193 shares of common stock through broker Morgan Stanley Smith Barney LLC on or about 01/15/2026, with an indicated aggregate market value of $1,916,235.51. The filing notes that these shares were acquired on the same date via a cash exercise of stock options from the issuer.
As context, the filing lists 109,819,569 shares of common stock outstanding and discloses that Justin Klee sold 7,715 shares of common stock on 01/06/2026 for gross proceeds of $85,589.44 during the prior three months. The seller also represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Amylyx Pharmaceuticals director reports stock gift. Director George M. Milne Jr filed a Form 4 showing a bona fide gift of 17,780 shares of Amylyx Pharmaceuticals, Inc. common stock on January 12, 2026. The shares were transferred for no consideration, meaning he did not receive payment for them. After this gift, he directly beneficially owned 812,881 shares of the company’s common stock.
Amylyx Pharmaceuticals, Inc. Chief Financial Officer James M. Frates reported an automatic sale of common stock. On January 6, 2026, he sold 3,326 shares of Amylyx common stock at a weighted average price of $11.1106 per share. According to the filing, these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units, and the sale was not at his discretion.
After this transaction, Frates directly beneficially owned 177,104 shares of Amylyx common stock. He also had indirect holdings through trusts, including 100,000 shares held by the JAMES M. FRATES 2025 GRAT No. 1 and additional blocks of 15,459 shares and 11,072 shares in other family trusts. For these trust holdings, he serves as trustee and disclaims beneficial ownership except to the extent of any pecuniary interest.
Amylyx Pharmaceuticals, Inc. director and Co-Chief Executive Officer Joshua B. Cohen reported an automatic sale of common stock. On January 6, 2026, he sold 7,715 shares of Amylyx common stock at a weighted average price of $11.0948 per share. According to the disclosure, these shares were required to be sold to cover tax withholding obligations arising from the vesting of restricted stock units, and the sales were automatic and not at his discretion.
After this transaction, Cohen beneficially owned 3,317,632 shares of Amylyx common stock, held directly.
Amylyx Pharmaceuticals Co-Chief Executive Officer Justin B. Klee reported an automatic sale of 7,715 shares of common stock on January 6, 2026. The shares were sold at a weighted average price of $11.0939 per share to cover tax withholding obligations arising from the vesting of restricted stock units, and the sale was not made at his discretion.
After this tax-related sale, Klee beneficially owned 3,317,586 shares of Amylyx Pharmaceuticals, Inc. common stock directly.
Amylyx Pharmaceuticals reported that it has selected AMX0318, a long-acting GLP-1 receptor antagonist, as a new development candidate for treating post-bariatric hypoglycemia and other rare diseases. AMX0318 was discovered through a research collaboration with Gubra A/S, which specializes in peptide-based drug discovery and preclinical research.
Under this collaboration, Gubra is eligible to receive more than $50 million in success-based development and commercialization milestone payments, plus mid-single digit royalties on worldwide net sales if AMX0318 progresses successfully. The selection and handover of the development candidate immediately triggers $4 million in milestone payments to Gubra.
Amylyx also updated its corporate presentation for use with investors and analysts, furnishing the new presentation as Exhibit 99.1.
Amylyx Pharmaceuticals (AMLX) filed its Q3 2025 report, showing a smaller quarterly loss as it reorients around its clinical pipeline. Net loss was $34.4 million versus $72.7 million a year ago, with basic and diluted net loss per share of $0.37 versus $1.07. Operating expenses fell to $36.0 million from $76.1 million, reflecting the absence of prior-year charges and reduced spend on discontinued programs.
Liquidity strengthened markedly. As of September 30, 2025, cash and cash equivalents were $225.2 million and marketable securities were $118.8 million. The company completed two underwritten offerings in 2025: 19.7 million shares at $3.50 for net proceeds of $65.5 million in January and 20.1 million shares at $10.00 for net proceeds of $190.7 million in September. Shares outstanding were 109,819,569 as of October 27, 2025.
Amylyx reports no product revenue in 2025 following the RELYVRIO/ALBRIOZA discontinuation. The company is advancing key programs: the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia (recruitment completion expected in the first quarter of 2026 with topline data in the third quarter of 2026) and the Phase 1 LUMINA trial of AMX0114 in ALS, with early cohort enrollment completed and initial data planned for scientific meetings.
Amylyx Pharmaceuticals (AMLX) reported that it issued a press release announcing financial results for the fiscal quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 to this report.
The information in this item, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act, and is not incorporated by reference into other filings except as expressly set forth by specific reference.
Amylyx Pharmaceuticals has a passive ownership filing showing that FMR LLC and Abigail P. Johnson together report beneficial ownership of 11,379,207 shares of common stock, representing 10.7% of the outstanding class. The filing shows FMR LLC holds 11,361,910 shares with sole voting power for that portion and sole dispositive power over 11,379,207 shares, while Abigail P. Johnson is reported with sole dispositive power over the full 11,379,207 shares and no voting power. The statement clarifies the stake is held in the ordinary course of business and not to change control.
Justin B. Klee, Co-Chief Executive Officer and a director of Amylyx Pharmaceuticals, Inc. (AMLX), reported sales of company common stock that were automatic to cover tax withholding on vested restricted stock units. On 09/30/2025 the reporting shows 29,775 shares sold at a weighted average price of $14.3728 and an additional 200 shares sold at a weighted average price of $15.01. After these transactions the filing reports total beneficial ownership of 3,325,301 shares (direct). The filing notes the sales were mandatory to satisfy tax obligations and were executed in multiple trades at prices within the disclosed ranges.